JPWO2020131899A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020131899A5 JPWO2020131899A5 JP2021534645A JP2021534645A JPWO2020131899A5 JP WO2020131899 A5 JPWO2020131899 A5 JP WO2020131899A5 JP 2021534645 A JP2021534645 A JP 2021534645A JP 2021534645 A JP2021534645 A JP 2021534645A JP WO2020131899 A5 JPWO2020131899 A5 JP WO2020131899A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pharmaceutical composition
- disorders
- anxiety
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 208000019901 Anxiety disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 16
- 230000036506 anxiety Effects 0.000 claims description 14
- 208000015114 central nervous system disease Diseases 0.000 claims description 13
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 12
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 12
- 208000012902 Nervous system disease Diseases 0.000 claims description 12
- 208000028017 Psychotic disease Diseases 0.000 claims description 12
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 12
- 230000001154 acute effect Effects 0.000 claims description 10
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims description 10
- 201000000980 schizophrenia Diseases 0.000 claims description 10
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 10
- 208000020401 Depressive disease Diseases 0.000 claims description 8
- 206010041250 Social phobia Diseases 0.000 claims description 8
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 8
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims description 8
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 8
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 8
- 150000003839 salts Chemical group 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 6
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 6
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 238000013019 agitation Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 6
- 208000024714 major depressive disease Diseases 0.000 claims description 6
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 6
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 6
- 208000019906 panic disease Diseases 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 4
- 208000008811 Agoraphobia Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000020706 Autistic disease Diseases 0.000 claims description 4
- 208000010235 Food Addiction Diseases 0.000 claims description 4
- 201000001916 Hypochondriasis Diseases 0.000 claims description 4
- 208000030990 Impulse-control disease Diseases 0.000 claims description 4
- 206010034158 Pathological gambling Diseases 0.000 claims description 4
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims description 4
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 235000014632 disordered eating Nutrition 0.000 claims description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 4
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 4
- 208000001836 Firesetting Behavior Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 201000004645 pyromania Diseases 0.000 claims description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 2
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 2
- 206010012239 Delusion Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000004547 Hallucinations Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 2
- 206010034912 Phobia Diseases 0.000 claims description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000000164 antipsychotic agent Substances 0.000 claims description 2
- 229940005529 antipsychotics Drugs 0.000 claims description 2
- 229960002430 atomoxetine Drugs 0.000 claims description 2
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims description 2
- 208000022266 body dysmorphic disease Diseases 0.000 claims description 2
- 229960001653 citalopram Drugs 0.000 claims description 2
- 229960004606 clomipramine Drugs 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 229960001623 desvenlafaxine Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229960003638 dopamine Drugs 0.000 claims description 2
- 229960002866 duloxetine Drugs 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- -1 esitalopram Chemical compound 0.000 claims description 2
- 229960002464 fluoxetine Drugs 0.000 claims description 2
- 229960004038 fluvoxamine Drugs 0.000 claims description 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 2
- 230000005176 gastrointestinal motility Effects 0.000 claims description 2
- 230000003370 grooming effect Effects 0.000 claims description 2
- 229960000685 levomilnacipran Drugs 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 229960000600 milnacipran Drugs 0.000 claims description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 229960005017 olanzapine Drugs 0.000 claims description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002296 paroxetine Drugs 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 229960004431 quetiapine Drugs 0.000 claims description 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 229960001534 risperidone Drugs 0.000 claims description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 2
- 229940076279 serotonin Drugs 0.000 claims description 2
- 229940121356 serotonin receptor antagonist Drugs 0.000 claims description 2
- 230000000697 serotonin reuptake Effects 0.000 claims description 2
- 229960002073 sertraline Drugs 0.000 claims description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 2
- 208000015891 sexual disease Diseases 0.000 claims description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004425 sibutramine Drugs 0.000 claims description 2
- 201000001716 specific phobia Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims description 2
- 239000003174 triple reuptake inhibitor Substances 0.000 claims description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004688 venlafaxine Drugs 0.000 claims description 2
- 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 claims 1
- 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 claims 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862780804P | 2018-12-17 | 2018-12-17 | |
| US62/780,804 | 2018-12-17 | ||
| PCT/US2019/066894 WO2020131899A1 (en) | 2018-12-17 | 2019-12-17 | Organic compound |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022514264A JP2022514264A (ja) | 2022-02-10 |
| JPWO2020131899A5 true JPWO2020131899A5 (https=) | 2022-12-23 |
| JP2022514264A5 JP2022514264A5 (https=) | 2022-12-23 |
| JP7487204B2 JP7487204B2 (ja) | 2024-05-20 |
Family
ID=71102816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534645A Active JP7487204B2 (ja) | 2018-12-17 | 2019-12-17 | 有機化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12195462B2 (https=) |
| EP (1) | EP3898221A4 (https=) |
| JP (1) | JP7487204B2 (https=) |
| KR (1) | KR20210104785A (https=) |
| CN (1) | CN113423568A (https=) |
| AU (1) | AU2019403150B2 (https=) |
| BR (1) | BR112021011792A2 (https=) |
| CA (1) | CA3121635A1 (https=) |
| IL (1) | IL283961A (https=) |
| MX (1) | MX2021007217A (https=) |
| WO (1) | WO2020131899A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108883111B (zh) | 2016-01-26 | 2021-10-08 | 细胞内治疗公司 | 有机化合物 |
| JP7224333B2 (ja) | 2017-07-26 | 2023-02-17 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| AU2019240226B2 (en) | 2018-03-23 | 2024-11-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| IL283963B2 (en) | 2018-12-17 | 2025-01-01 | Intra Cellular Therapies Inc | Synthesis of condensed gamma-carbolines and converted heterocycles |
| US12195463B2 (en) | 2018-12-21 | 2025-01-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2020132605A1 (en) | 2018-12-21 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP4665344A1 (en) * | 2023-02-17 | 2025-12-24 | Intra-Cellular Therapies, Inc. | Lumateperone and derivatives thereof for modulating the nervous system |
| CN120192319B (zh) * | 2023-12-22 | 2026-02-06 | 江苏恩华药业股份有限公司 | 一种卢美哌隆中间体化合物的制备方法 |
| WO2026011166A1 (en) | 2024-07-03 | 2026-01-08 | Intra-Cellular Therapies, Inc. | Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| ATE59289T1 (de) | 1985-10-09 | 1991-01-15 | Desitin Arzneimittel Gmbh | Verfahren zur herstellung einer darreichungsund dosierungsform fuer arzneimittel-wirkstoffe, reagentien oder andere wirkstoffe. |
| HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| CN1074923C (zh) | 1993-11-19 | 2001-11-21 | 詹森药业有限公司 | 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类 |
| WO2000035419A2 (en) | 1998-12-17 | 2000-06-22 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
| MXPA01012969A (es) | 1999-06-15 | 2003-10-14 | Bristol Myers Squibb Pharma Co | Gamma-carbolinas fusionadas de heterociclo sustituido. |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| PL366233A1 (en) | 2000-12-20 | 2005-01-24 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| US7592454B2 (en) | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
| EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
| EP2068872A1 (en) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| KR102065319B1 (ko) | 2007-03-12 | 2020-01-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| AU2009212065B2 (en) | 2008-02-05 | 2014-03-20 | Clera Inc. | Compositions and methods for alleviating depression or improving cognition |
| JP5611846B2 (ja) | 2008-03-12 | 2014-10-22 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 置換ヘテロ環縮合ガンマ−カルボリン類固体 |
| CN105168219B (zh) | 2008-05-27 | 2018-11-20 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
| EP2560676B8 (en) | 2010-04-22 | 2016-10-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
| TWI582092B (zh) | 2010-07-28 | 2017-05-11 | 歌林達股份有限公司 | 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物 |
| DE102010041942B4 (de) | 2010-10-04 | 2013-01-17 | Lear Corporation | Bewegliche Kopfstützen für Fahrzeugsitze |
| CN105997521B (zh) | 2011-08-16 | 2018-12-25 | 株式会社东商 | 片剂分割装置 |
| WO2013155504A1 (en) | 2012-04-14 | 2013-10-17 | Intra-Cellular Therapies, Inc. | Novel methods |
| SG11201501894VA (en) | 2012-09-14 | 2015-04-29 | Abbvie Inc | Tricyclic quinoline and quinoxaline derivatives |
| HUE053159T2 (hu) | 2013-03-15 | 2021-06-28 | Intra Cellular Therapies Inc | Szerves vegyületek |
| CN105706016B (zh) | 2013-09-11 | 2019-07-19 | 欧力天工美国公司 | 用于时钟同步的系统、方法和移动设备 |
| IL305990B2 (en) | 2013-12-03 | 2025-12-01 | Intra Cellular Therapies Inc | Long-acting injectable composition comprising polymeric microspheres of heterocycle fused gamma-carboline compounds or a pharmaceutical composition for sustained or delayed release comprising the compounds and their use in the treatment of bipolar disorder i and/or bipolar ii disorder |
| RU2016143091A (ru) | 2014-04-04 | 2018-05-08 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| MX365969B (es) | 2014-04-04 | 2019-06-21 | Intra Cellular Therapies Inc | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. |
| WO2015191554A1 (en) | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| WO2017117514A1 (en) | 2015-12-31 | 2017-07-06 | Tung Roger D | Deuterated iti-007 |
| CN108883111B (zh) | 2016-01-26 | 2021-10-08 | 细胞内治疗公司 | 有机化合物 |
| PL3407889T3 (pl) * | 2016-03-25 | 2021-11-22 | Intra-Cellular Therapies, Inc. | Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego |
| US20200392135A1 (en) | 2016-03-25 | 2020-12-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US11014925B2 (en) | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
| JP2019513143A (ja) | 2016-03-28 | 2019-05-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規塩類および結晶 |
| EP4001281A1 (en) | 2016-08-09 | 2022-05-25 | Teva Pharmaceuticals International GmbH | Solid state forms of lumateperone ditosylate salt and preparation thereof |
| US10906906B2 (en) | 2016-12-29 | 2021-02-02 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
| AU2018234931B2 (en) | 2017-03-17 | 2022-05-26 | Blackthorn Therapeutics, Inc. | Kappa opioid receptor antagonists and products and methods related thereto |
| IL268970B2 (en) | 2017-03-24 | 2023-12-01 | Intra Cellular Therapies Inc | Oral transmucosal formulations of substituted heterocycle fused gamma carbolines |
| JP7223742B2 (ja) | 2017-07-26 | 2023-02-16 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| JP7224333B2 (ja) | 2017-07-26 | 2023-02-17 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| AU2019240226B2 (en) | 2018-03-23 | 2024-11-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| US20220160704A2 (en) | 2018-08-08 | 2022-05-26 | Torralva Medical Therapeutics Llc | Compositions for opiate and opioid prevention and reversal, and methods of their use |
| WO2020132605A1 (en) | 2018-12-21 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US12195463B2 (en) | 2018-12-21 | 2025-01-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10668097B1 (en) | 2019-03-21 | 2020-06-02 | Direct Digital, LLC | Testosterone enhancing compositions and methods |
| EP3946345A4 (en) | 2019-04-04 | 2023-01-04 | Intra-Cellular Therapies, Inc. | METHODS OF TREATMENT OF NEUROPATHIC PAIN |
| CA3139168A1 (en) | 2019-05-07 | 2020-11-12 | Nirsum Laboratories, Inc. | Opioid receptor antagonist prodrugs |
-
2019
- 2019-12-17 BR BR112021011792-0A patent/BR112021011792A2/pt unknown
- 2019-12-17 KR KR1020217021974A patent/KR20210104785A/ko active Pending
- 2019-12-17 CA CA3121635A patent/CA3121635A1/en active Pending
- 2019-12-17 EP EP19900775.8A patent/EP3898221A4/en active Pending
- 2019-12-17 JP JP2021534645A patent/JP7487204B2/ja active Active
- 2019-12-17 US US17/415,565 patent/US12195462B2/en active Active
- 2019-12-17 AU AU2019403150A patent/AU2019403150B2/en active Active
- 2019-12-17 WO PCT/US2019/066894 patent/WO2020131899A1/en not_active Ceased
- 2019-12-17 CN CN201980091790.XA patent/CN113423568A/zh active Pending
- 2019-12-17 MX MX2021007217A patent/MX2021007217A/es unknown
-
2021
- 2021-06-14 IL IL283961A patent/IL283961A/en unknown
-
2024
- 2024-12-04 US US18/968,542 patent/US20250092045A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shelton | Serotonin and norepinephrine reuptake inhibitors | |
| CN1832734B (zh) | 用于治疗抑郁症的取代的2-氨基1,2,3,4-四氢化萘 | |
| JP2005539068A5 (https=) | ||
| RU2445973C2 (ru) | Способ лечения глубокой депрессии у человека | |
| JP2021519267A5 (https=) | ||
| JP2013544850A5 (https=) | ||
| RU2005128548A (ru) | Применение (1s,2r) этантиомера милнаципрана для получения лекарственного средства | |
| KR20090029200A (ko) | 우울증 질환에 대한 치료 | |
| ZA200006817B (en) | Combination therapy for treatment of Bipolar Disorders. | |
| JPWO2020131899A5 (https=) | ||
| RU2008131331A (ru) | Производные карбостирила и ингибиторы обратного захвата серотонина для лечения эмоциональных расстройств | |
| JP2010534676A5 (https=) | ||
| JP2005523334A5 (https=) | ||
| RU2020125170A (ru) | Композиции и способы улучшения биодоступности 5-гидрокситриптофана | |
| US20040229943A1 (en) | Analeptic and drug combinations | |
| JPWO2019183546A5 (https=) | ||
| JP2021511365A5 (https=) | ||
| JPWO2020132474A5 (https=) | ||
| ES2390225T3 (es) | Combinación del analéptico modafinilo y de un antidepresivo para el tratamiento de la depresión | |
| CA2716966A1 (en) | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | |
| JP2018508556A5 (https=) | ||
| US20040242698A1 (en) | Analeptic and antidepressant combinations | |
| JP2011516604A (ja) | 鬱病患者の自殺行動の予防治療のためのミルナシプラン塩酸塩の（１ｓ，２ｒ）鏡像異性体の使用 | |
| RU2021121046A (ru) | Органическое соединение | |
| JP5341037B2 (ja) | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 |